Genentech Launches Direct-to-Patient Xofluza Access Program
SOUTH SAN FRANCISCO, CA – October 16, 2025: Genentech, a member of the Roche Group, has introduced its first...
Antiretroviral Research
Advertisement
Merck’s Two-Drug HIV Therapy Shows Strong Phase 3 Efficacy
RAHWAY, N.J. – October 15, 2025 — Merck (NYSE: MRK) announced new Phase 3 trial results for its investigational,...
Advertisement
